114 related articles for article (PubMed ID: 21460786)
21. Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?
Cuccurullo V; Di Stasio GD; Prisco MR; Mansi L
Indian J Radiol Imaging; 2017; 27(4):509-516. PubMed ID: 29379249
[TBL] [Abstract][Full Text] [Related]
22. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
23. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
24. [Immunological imaging using tagged octreotide].
Cascini GL; Cuccurullo V; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):129-33. PubMed ID: 11753235
[TBL] [Abstract][Full Text] [Related]
25. Preclinical studies of SPECT and PET tracers for NET.
Brom M; Boerman O; Gotthardt M; Oyen WJ
PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
[TBL] [Abstract][Full Text] [Related]
26. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
28. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
[TBL] [Abstract][Full Text] [Related]
29. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
30. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
32. Cancer with unknown primary: finding a needle in a hay stack.
Giesel FL; Mehndiratta A; Mafomane MP; Zechmann CM; Bergmann F; Schemmer P; Haberkorn U; Kratochwil C
Exp Oncol; 2012; 34(1):64-5. PubMed ID: 22453152
[TBL] [Abstract][Full Text] [Related]
33. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
34. ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.
Naswa N; Sharma P; Kumar A; Soundararajan R; Kumar R; Malhotra A; Ammini AC; Bal C
Clin Nucl Med; 2012 Mar; 37(3):245-51. PubMed ID: 22310250
[TBL] [Abstract][Full Text] [Related]
35. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
36. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
Nauck C; Ivancević V; Emrich D; Creutzfeldt W
Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
[TBL] [Abstract][Full Text] [Related]
37. Nuclear imaging of neuroendocrine tumours.
Sundin A; Garske U; Orlefors H
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings.
Kuyumcu S; Adalet I; Sanli Y; Turkmen C; Ozkan ZG; Yilmazbayhan D
Ann Nucl Med; 2012 Nov; 26(9):689-97. PubMed ID: 22802007
[TBL] [Abstract][Full Text] [Related]
39. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
40. Update on nuclear medicine imaging of neuroendocrine tumors.
Goldsmith SJ
Future Oncol; 2009 Feb; 5(1):75-84. PubMed ID: 19243300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
